Skip to content

Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing

Randomized Multicenter Study on the Management of Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04764864
Enrollment
0
Registered
2021-02-21
Start date
2022-01-01
Completion date
2022-01-01
Last updated
2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodynamic Instability, Pelvic Fracture, Trauma

Keywords

Trauma, Pelvis Fracture, Hypovolemic Shock, Preperitoneal Pelvic Packing, Angioembolization, Hemodynamic Instability

Brief summary

Pelvic fracture is a usual injury in trauma patients. An unstable trauma patient with a pelvic fracture has an elevated risk of death due to pelvic bleeding and the associated injuries. Traditionally, it has been estimated that the main source of bleeding is venous and, consequently, the main treatment has been the preperitoneal pelvic packing. Nevertheless, according to new data, arterial bleeding appears to be a more important source of pelvic bleeding than it was thought and angioembolization seems to be a good alternative in the treatment of these injuries. Consequently, it is important to define better the management of these patients. This investigation project consists in a clinical trial study, performed by a multidisciplinary team of many hospitals around the country, in which angioembolization and preperitoneal pelvic packing are compared. Unstable trauma patients with a pelvic fracture and no other injuries (negative FAST / peritoneal aspiration, no evidence of bone fractures or thoracic injuries) will be submitted, in less than 60 minutes from hospital arrival, to angioembolization or preperitoneal pelvic packing, according to randomization. There will be a specific timing evaluation of different markers: hemodynamic (vital signs at arrival, immediately and 24 hours after treatment) and analytic (at arrival and upon entering to the Intensive Care Unit). Registered variables include: blood cell transfusions, vasoactive drug requirements, time elapsed between hospital admission and intervention, treatment duration, need of other strategies to stop pelvic bleeding, complications and mortality. The objective of this study is to determinate if angioembolization is superior to preperitoneal pelvic packing for pelvic bleeding control in unstable trauma patients due to pelvic bleeding.

Interventions

Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed. In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated. The material used will vary depending on the characteristics of the injury and the availability of the materials.

PROCEDUREPreperitoneal Pelvic Packing

Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified. Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect. A second intervention is required to remove the material in 24-48 hours.

Sponsors

Corporacion Parc Tauli
CollaboratorOTHER
Nuria Llorach-Perucho
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Systolic blood pressure ≤ 90 mmHg * Heart rate \> 100 bpm * Shock Index ≥ 0,8 * Pelvic fracture * Negative FAST / peritoneal aspiration

Exclusion criteria

* Other causes of bleeding that require treatment

Design outcomes

Primary

MeasureTime frameDescription
Pelvic bleeding control based on clinical response24 hoursClinical response after the intervention

Secondary

MeasureTime frameDescription
Additional techniquesThrough study completion, an average of 2 yearsNeed for additional techniques after the intervention to control bleeding associated with pelvic fracture
Post-procedure complicationsThrough study completion, an average of 2 yearsPresence of post-procedure complications
Post-procedure complications degreeThrough study completion, an average of 2 yearsDescription of post-procedure complications: Clavien Dindo scale
MortalityThrough study completion, an average of 2 yearsDeath of the pacient (cause and date)
Blood cell transfusionThrough study completion, an average of 2 yearsNeed for blood cell transfusion for patients (number and need for masive transfusion protocol activation)
Time until interventionTime until intervention (up to 60 minutes)Time elapsed between hospital admission and intervention

Other

MeasureTime frameDescription
Time until arrival at hospitalTime until arrival at hospital (up to 30 minutes)Time elapsed between prehospital attention and hospital admission
Duration of angioembolizationThrough study completion, an average of 2 yearsDuration of angioembolization
Angioembolization treatmentThrough study completion, an average of 2 yearsArteries treated with angioembolization
Duration of Preperitoneal Pelvic PackingThrough study completion, an average of 2 yearsDuration of Preperitoneal Pelvic Packing
Intensive care unit stayThrough study completion, an average of 2 yearsNumber of days that the patient remains in the intensive care unit
Hospital stayThrough study completion, an average of 2 yearsNumber of days that the patient remains in hospital
Readmission30 days after dischargeReadmission 30 days after discharge

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026